These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

491 related articles for article (PubMed ID: 23755891)

  • 41. Targeting triple negative breast cancer: is p53 the answer?
    Turner N; Moretti E; Siclari O; Migliaccio I; Santarpia L; D'Incalci M; Piccolo S; Veronesi A; Zambelli A; Del Sal G; Di Leo A
    Cancer Treat Rev; 2013 Aug; 39(5):541-50. PubMed ID: 23321033
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Aminoflavone-loaded EGFR-targeted unimolecular micelle nanoparticles exhibit anti-cancer effects in triple negative breast cancer.
    Brinkman AM; Chen G; Wang Y; Hedman CJ; Sherer NM; Havighurst TC; Gong S; Xu W
    Biomaterials; 2016 Sep; 101():20-31. PubMed ID: 27267625
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Among triple-negative breast cancers, HER2(0) breast cancer shows a strong tendency to be basal-like compared with HER2(1+) breast cancer: preliminary results.
    Nakagawa M; Bando Y; Nagao T; Takai C; Ohnishi T; Honda J; Moriya T; Izumi K; Takahashi M; Tangoku A; Sasa M
    Breast Cancer; 2012 Jan; 19(1):54-9. PubMed ID: 21465226
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The functional role of Notch signaling in triple-negative breast cancer.
    Speiser JJ; Erşahin C; Osipo C
    Vitam Horm; 2013; 93():277-306. PubMed ID: 23810012
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Frequently increased epidermal growth factor receptor (EGFR) copy numbers and decreased BRCA1 mRNA expression in Japanese triple-negative breast cancers.
    Toyama T; Yamashita H; Kondo N; Okuda K; Takahashi S; Sasaki H; Sugiura H; Iwase H; Fujii Y
    BMC Cancer; 2008 Oct; 8():309. PubMed ID: 18950515
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Preclinical Evaluation of Fatty Acid Synthase and EGFR Inhibition in Triple-Negative Breast Cancer.
    Giró-Perafita A; Palomeras S; Lum DH; Blancafort A; Viñas G; Oliveras G; Pérez-Bueno F; Sarrats A; Welm AL; Puig T
    Clin Cancer Res; 2016 Sep; 22(18):4687-97. PubMed ID: 27106068
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Identification of a novel inhibitor of triple-negative breast cancer cell growth by screening of a small-molecule library.
    Fujita T; Mizukami T; Okawara T; Inoue K; Fujimori M
    Breast Cancer; 2014 Nov; 21(6):738-47. PubMed ID: 23456737
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Sequential Combination Therapy of CDK Inhibition and Doxorubicin Is Synthetically Lethal in p53-Mutant Triple-Negative Breast Cancer.
    Jabbour-Leung NA; Chen X; Bui T; Jiang Y; Yang D; Vijayaraghavan S; McArthur MJ; Hunt KK; Keyomarsi K
    Mol Cancer Ther; 2016 Apr; 15(4):593-607. PubMed ID: 26826118
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Raloxifene reduces triple-negative breast cancer tumor growth and decreases EGFR expression.
    Taurin S; Allen KM; Scandlyn MJ; Rosengren RJ
    Int J Oncol; 2013 Sep; 43(3):785-92. PubMed ID: 23842642
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The Evolution of Triple-Negative Breast Cancer: From Biology to Novel Therapeutics.
    Anders CK; Abramson V; Tan T; Dent R
    Am Soc Clin Oncol Educ Book; 2016; 35():34-42. PubMed ID: 27249684
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A phase 1/2 of a combination of cetuximab and taxane for "triple negative" breast cancer patients.
    Nechushtan H; Vainer G; Stainberg H; Salmon AY; Hamburger T; Peretz T
    Breast; 2014 Aug; 23(4):435-8. PubMed ID: 24836394
    [TBL] [Abstract][Full Text] [Related]  

  • 52. MDM4 is a rational target for treating breast cancers with mutant p53.
    Miranda PJ; Buckley D; Raghu D; Pang JB; Takano EA; Vijayakumaran R; Teunisse AF; Posner A; Procter T; Herold MJ; Gamell C; Marine JC; Fox SB; Jochemsen A; Haupt S; Haupt Y
    J Pathol; 2017 Apr; 241(5):661-670. PubMed ID: 28097652
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Quantum dot-based in situ simultaneous molecular imaging and quantitative analysis of EGFR and collagen IV and identification of their prognostic value in triple-negative breast cancer.
    Zheng HM; Chen C; Wu XH; Chen J; Sun S; Sun JZ; Wang MW; Sun SR
    Tumour Biol; 2016 Feb; 37(2):2509-18. PubMed ID: 26385773
    [TBL] [Abstract][Full Text] [Related]  

  • 54. PEA-15 facilitates EGFR dephosphorylation via ERK sequestration at increased ER-PM contacts in TNBC cells.
    Shin M; Lee KE; Yang EG; Jeon H; Song HK
    FEBS Lett; 2015 Apr; 589(9):1033-9. PubMed ID: 25796184
    [TBL] [Abstract][Full Text] [Related]  

  • 55. COTI-2 reactivates mutant p53 and inhibits growth of triple-negative breast cancer cells.
    Synnott NC; O'Connell D; Crown J; Duffy MJ
    Breast Cancer Res Treat; 2020 Jan; 179(1):47-56. PubMed ID: 31538264
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Lapatinib-induced annexin A6 upregulation as an adaptive response of triple-negative breast cancer cells to EGFR tyrosine kinase inhibitors.
    Widatalla SE; Korolkova OY; Whalen DS; Goodwin JS; Williams KP; Ochieng J; Sakwe AM
    Carcinogenesis; 2019 Aug; 40(8):998-1009. PubMed ID: 30590459
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer.
    Montero JC; Esparís-Ogando A; Re-Louhau MF; Seoane S; Abad M; Calero R; Ocaña A; Pandiella A
    Oncogene; 2014 Jan; 33(2):148-56. PubMed ID: 23246963
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Triple-negative breast cancer: investigating potential molecular therapeutic target.
    Papa A; Caruso D; Tomao S; Rossi L; Zaccarelli E; Tomao F
    Expert Opin Ther Targets; 2015 Jan; 19(1):55-75. PubMed ID: 25307277
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Updates in the treatment of basal/triple-negative breast cancer.
    Shastry M; Yardley DA
    Curr Opin Obstet Gynecol; 2013 Feb; 25(1):40-8. PubMed ID: 23222093
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Induction of fibronectin in response to epidermal growth factor is suppressed by silibinin through the inhibition of STAT3 in triple negative breast cancer cells.
    Kim S; Jeon M; Lee J; Han J; Oh SJ; Jung T; Nam SJ; Kil WH; Lee JE
    Oncol Rep; 2014 Nov; 32(5):2230-6. PubMed ID: 25175149
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.